600% drug – RFK Jr. defended TrumpRx discount claims using nonstandard “percentage” examples. Misryoum explains the correct math and what it means for public trust and health costs.
President Donald Trump has repeatedly framed drug-price discounts on his watch as being greater than 100%—a claim that has faced scrutiny because, by standard math, discounts above that level can’t happen in the way the administration describes.
At a Senate Finance Committee hearing on April 22, Health and Human Services Secretary Robert F.. Kennedy Jr.. tried to back up Trump’s messaging when Sen.. Elizabeth Warren pressed him on discount figures advertised through the federally run TrumpRx website.. Warren questioned the plausibility of claims that discounts could reach 600%.
Kennedy’s explanation leaned on a simple. but nonstandard example: he said that if a $600 drug were “reduced” to $10. that should be understood as a “600% reduction.” A day later. at an Oval Office event. Kennedy repeated the same framework.. He also tied the math to a broader argument—that the numbers were meant to show the scale of what the administration calls theft or overcharging tied to drug prices.
The math dispute behind TrumpRx discount claims
The key issue is that percent change has a standard definition in economics and in basic financial literacy: percentage decrease is calculated using the original price as the baseline. In the example Kennedy used—dropping from $600 to $10—the decrease is not 600%.
Using the conventional method, you subtract the new price from the original price, then divide by the original price.. Here, that means $600 minus $10 equals $590.. Divide $590 by $600, and the result is about 0.983, or a 98.3% decrease.. In other words, the consumer pays less, but the discount cannot exceed 100% unless the seller is actually paying the buyer.
A 100% reduction would mean the patient pays nothing for the medication.. If a “reduction” were 200% in the conventional sense. it would imply the manufacturer pays the consumer an amount equal to the drug’s price—an outcome that doesn’t align with how retail purchasing works for prescription drugs.. As the percentage numbers rise further above 100%. the implication becomes increasingly extreme: the math stops describing a typical discount and starts describing a payment from the seller to the buyer.
Why percentage framing matters in U.S. health policy
While this may sound like a technical dispute, public policy doesn’t operate on spreadsheets alone.. The way a government explains drug pricing directly shapes public expectations—how much people think they can save. what they believe is possible. and whether they feel confident in the information coming from Washington.
For patients and families. the practical stakes are straightforward: drug affordability is already strained for many households. and trust is the currency that turns price policy into real-world behavior.. If officials describe savings in ways that are mathematically inconsistent, consumers may walk away with distorted expectations.. And when those expectations collide with checkout totals, frustration can harden into skepticism about future reforms.
There’s also a political dimension.. Drug pricing is one of the most visible arenas for claims about competence and results.. When leaders present numbers that don’t hold up under basic scrutiny. it gives critics an opening—and it puts the administration in the position of defending not only policy choices. but the presentation of those choices.
Misryoum sees this as part of a wider pattern: administrations often use vivid percentage language to dramatize perceived unfairness.. But vivid does not automatically mean accurate.. If the public can’t understand the method, the message risks becoming political theater rather than actionable information.
The credibility test for claims above 100%
Mathematical principles allow for one kind of “600%” story and rule out another.. It’s possible to increase a price by 600%—for example, if something goes up multiple times its original cost.. But a discount described as “600%” in a reduction scenario signals a level of savings that. under the standard definition. can’t occur while the consumer still has to pay anything.
Kennedy and Trump have used similar framing before, according to the record of prior statements that have drawn fact-check scrutiny.. Yet in these exchanges, the administration has not convincingly addressed the underlying definition of percentage change itself.. That gap is exactly what the Senate questioning exposed: the administration may be using “percentage” as rhetorical shorthand. but the public policy stakes demand a standard calculation.
Misryoum also notes the broader consequence for federal messaging around drug pricing: if discount claims are communicated in a way that departs from shared mathematical conventions. it becomes harder for watchdogs. legislators. and even ordinary consumers to verify what the figures mean.. In a policy space already crowded with complex pricing structures—copays, rebates, negotiated rates—clarity is not a luxury.. It’s the difference between a policy promise that can be trusted and one that invites doubt.
What comes next for TrumpRx and congressional oversight
Congress has a way of forcing the “how” out of the “wow” in government claims.. Warren’s line of questioning reflects a demand not just for outcomes. but for the math used to sell those outcomes.. If TrumpRx discount figures continue to be defended through unconventional percentage explanations. oversight may intensify. and future hearings may spend more time on definitions than on mechanisms.
For the administration, the path forward is simple in principle but difficult in practice: align discount language with standard percentage change calculations, or at least clearly explain the alternative method in a way that matches how consumers and policymakers interpret savings.
Because in drug pricing, the public doesn’t just want to hear that prices are coming down. They want to know exactly how much—what the discount means mathematically, what it means at the pharmacy counter, and whether the government’s confidence rests on numbers that can withstand basic scrutiny.